Novartis AG
METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS

Abstract:

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.